An advocate general (AG) has said that regulatory authorities in “concerned” EU member states handling drug marketing authorisations (MAs) are co-responsible for approved documents on data exclusivity.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Advocate general, data exclusivity, CJEU, Court of Justice of the European Union, Helm, Astellas, medicine, marketing authorisation
